[Iron supplementation in chronic kidney disease]

Area of Science:

• Nephrology
• Hematology
• Pharmacology

Background:

• Anemia is a common complication in chronic kidney disease (CKD) patients.
• Iron preparations are a primary treatment for CKD-related anemia.
• Traditional iron therapies (oral and intravenous) have limitations, including poor absorption, gastrointestinal issues, and adverse effects.

Purpose of the Study:

• To review the challenges associated with conventional iron therapy for anemia in CKD.
• To explore the potential of novel iron formulations in managing CKD anemia.
• To highlight the benefits of ferric pyrophosphate and liposomal iron.

Main Methods:

• Literature review of studies on iron therapy in chronic kidney disease.
• Analysis of efficacy and safety profiles of different iron preparations.
• Comparison of traditional versus modern iron delivery methods.

Main Results:

• Oral iron is often ineffective in CKD due to malabsorption and gastrointestinal side effects.
• Intravenous iron, while effective, carries risks of serious adverse events.
• Ferric pyrophosphate (added to dialysis fluid) and liposomal iron show promise with improved tolerability and efficacy.

Conclusions:

• Novel iron formulations represent a significant advancement in treating anemia in CKD patients.
• Ferric pyrophosphate and liposomal iron offer alternatives with potentially fewer adverse effects.
• These modern iron agents may improve patient outcomes and adherence in CKD anemia management.